Home›Trial›NCT03992755
NCT03992755Phase 3ACTIVE NOT RECRUITING

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Study Summary

The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).

Conditions
Primary Pulmonary Hypertension
Interventions / Drugs
LIQ861 Inhaled Treprostinil
View on ClinicalTrials.gov ↗
Sponsor
LQDA
Liquidia Technologies
Pulmonary
D35/100
Study Details
Enrollment92 participants
Primary Completion—
Lead SponsorLiquidia Technologies, Inc.
Data Retrieved2026-04-11 04:20:00.960800+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 92 participants
Sponsor Catalyst Profile

Liquidia Technologies (LQDA) is the sponsoring company for this trial. BiotechSign currently grades this company D (35/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

LQDA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.